Strong 26% growth, margin expansion; long-term bets ramping slower than guided

CFO confirmed export revenues grew 46%; domestic +12%

Gross margin 78.9%, exactly 100 bps YoY expansion confirmed

Injectable at 5% utilization in Q1; only in-house branded product supply; external sales expected H2 FY27+

Ankur confirmed pricing was primary driver of wallet share gains on existing products; €1.25B fermentation capacity

Clarified to FY28 due to slower injectable facility ramp; 32% current, expect H2 FY27 improvement but full 40% by FY28

Was guided as end-FY27 target; now clarified to FY28 due to slower injectable facility ramp from expected delays in approvals/qualifications.

Q1 at 5% utilization vs near-ramp expectations; external contract manufacturing to start H2 FY27 (not Q1). Facility working, but demand pull slower.

No change; Q1 delivered 26% growth supports trajectory. Long-term ₹3,000 Cr vision unchanged; phasing of infrastructure ramp extended by 1-2 quarters.

Some spillover from Q4 FY26 delays, but majority from new products and broad geographic sales expansion (US, Europe, Japan, LatAm). On track for >historical growth rates FY27.

₹600-700 Cr formulations, ₹2,200-2,300 Cr APIs (injectables embedded). Injectables at nascent stage, oral solids ramping on new product launches. 5-6 years to near ₹3,000 Cr via CAGR.

All equally nascent and exciting. Stellon has ANDA approvals; injectables large addressable market (₹600 Cr potential), only integrated player in India; CDMO few global competitors, lengthy sales cycle. All 3 on table.

Unit 1: 80%, Unit 3: 55%, Unit 2: 25%. Anti-infectives, oncology higher growth than immuno. CDMO 1-2% of sales, intent to double-digit. Domestic formulation: Middle East tender loss (-contribution); ex-that, nephrology & critical care up double-digits.

Forex 10-12% movement; net impact 3-5% to EBITDA (offset by input costs). Constant currency growth ~3-4% on top of 26%, so ~21%.

Primarily pricing, driven by fermentation capacity economies of scale. Existing products; new product conversions lower scale yet but visible. Soft aspects (fermentation partnership) secondary.

Operating leverage + renewables will drive margins better than sales growth. But need injectable & Stellon ramping to reach 40%; expect partial this year, fuller by FY28.

Commercialized; exhibit batches on stability, filings underway. 12-15 months for emerging market approvals = next year. Focus H1 FY27 on domestic (own branded + contract). External sales Q2 H2 FY27.

5% utilization. EBITDA breakeven level unknown (promised to follow up). Couple million $ CDMO sales from one animal health project.

No customer feedback on concerns yet.

Historically paid dividends; exploring organic and inorganic growth in fermentation adjacencies (peptides, veterinary, etc.). All 3 options on table.

Added 2 customers last year; couple more projects progressing, expect advanced stage/closure by year-end. Leverage scale, capacity, expertise, long-standing relationships.

Delayed couple quarters (inspections, approvals, facility qualification). Now on track as of Q1 FY27. First step critical; going forward on track.

Unit 3 at 55% includes KSM manufacturing (sourced or in-house). Nystatin, fusidic acid ramps drive Unit 3 growth. Pipeline: 8-10 products, mostly anti-infectives for Unit 3 (high-value oncology in small 5K-L fermenter). Capacity utilization doesn't linearly reflect revenue (high-value oncology products).

Q1 delivered 26% growth; pipeline visibility strong; export momentum +46%; new products ramping.

Infrastructure built/planned (fermentation capacity, injectable facility); dependent on new initiatives scaling (CDMO ramp, injectables utilization)

Currently 32% (+190 bps YoY); expects operating leverage + renewables + injectable ramp to drive. Ex-injectable/Stellon start-up costs, would be 37% in Q1.

Injectable at 5% utilization; management confident on margin trajectory post-ramp, but dependent on contract manufacturing onboarding.

Currently 55% (ex-KSM mfg); ample land (160 acres, only 20-25% used). May add capacity for fermentation adjacencies (peptides, veterinary) if dedicated requirements arise.

Injectable at 5% utilization; Stellon just launched (no revenue); CDMO 1-2% of sales. Margin target 40% deferred to FY28 (from end-FY27). All 3 critical to ₹3,000 Cr vision.

Management references 'marquee customers' and 'advanced discussions with several large customers' but withholds specific customer names, wallet share, or concentration metrics.

10-12% dollar movement YoY; net EBITDA impact 3-5% after input cost absorption. Ongoing watch on currency and commodity prices.

Analyst raised concern about 100% tariff on generics from US in 2 years; potential impact on API and formulation sales to US customers and their supply chains.

Formulation revenue -23% YoY; ex-Middle East tender loss, underlying domestic up double-digits. But strategy to address via APIs for addressable markets may continue to pressure formulation mix.